This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Incyte Reports 2012 Fourth-Quarter And Full-Year Financial Results; Provides 2013 Financial Guidance; Updates Shareholders On Key Clinical Programs

Stocks in this article: INCY

Net Income/Loss

Quarter Ended December 31, 2012

Net income for the quarter ended December 31, 2012, was $18.8 million, or $0.14 per basic and diluted share, as compared to a net loss of $55.1 million, or $0.44 per basic and diluted share, for the same period in 2011. The change from a net loss in the fourth quarter of 2011 to net income in the fourth quarter of 2012 is primarily due to a full quarter of Jakafi product revenues and a $50.0 million milestone payment earned under our collaboration with Lilly related to baricitinib.

Year Ended December 31, 2012

Net loss for the full year 2012 was $44.3 million, or $0.34 per basic and diluted share as compared to a net loss of $186.5 million, or $1.49 per basic and diluted share, for the full year 2011. The decrease in net loss from 2011 to 2012 is primarily due to a full year of Jakafi product revenue and $90.0 million in milestone payments earned under our collaborations with Lilly and Novartis.

Non-Cash Stock Option Expense

Included in net income for the quarter ended December 31, 2012, was $9.1 million of non-cash expense related to employee stock options, of which $6.0 million was included in research and development expenses and $3.1 million was included in selling, general and administrative expenses. Included in net loss for the quarter ended December 31, 2011, was $7.4 million of non-cash expense related to employee stock options, of which $4.6 million was included in research and development expenses and $2.8 million was included in selling, general and administrative expenses.

Included in net loss for the year ended December 31, 2012, was $38.5 million of non-cash expense related to employee stock options, of which $25.5 million was included in research and development expenses and $13.0 million was included in selling, general and administrative expenses. Included in net loss for the year ended December 31, 2011, was $29.0 million of non-cash expense related to employee stock options, of which $18.6 million was included in research and development expenses and $10.4 million was included in selling, general and administrative expenses.

2 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs